文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗儿童及青少年重度慢性斑块状银屑病的长期疗效、安全性与耐受性:一项III期双盲随机对照试验的两年结果

Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomized controlled trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-03-27

该III期双盲随机对照试验评估司库奇尤单抗在6至<18岁重度慢性斑块状银屑病患者中的长期疗效与安全性。治疗104周后,PASI 75/90/100及IGA mod 2011 0/1应答持续维持,CDLQI 0/1应答在低剂量组为61.1%、高剂量组为65.0%,安全性特征与已知一致。

要点

  • 司库奇尤单抗治疗至第104周时PASI 75/90/100及IGA mod 2011 0/1应答持续维持。
  • 第2年治疗期间,PASI 75和IGA mod 2011 0/1应答在低剂量与高剂量组间相似。
  • CDLQI 0/1应答在低剂量组为61.1%,高剂量组为65.0%。

核心结论

  • 司库奇尤单抗在儿童重度慢性斑块状银屑病患者中显示出持续长期疗效(长达2年)和良好安全性(约320患者年治疗)。

研究设计与样本

  • III期双盲随机对照试验,纳入6至<18岁重度慢性斑块状银屑病患者(NCT02471144)。
  • 52周后患者继续接受司库奇尤单抗低剂量(75/150 mg)或高剂量(75/150/300 mg)治疗。
  • 依那西普(0.8 mg/kg)治疗至第52周的患者进入随访。
  • 分析包括从开始即接受司库奇尤单抗低剂量及从安慰剂转换至低剂量的患者(“Any secukinumab”低剂量组),以及从开始即接受高剂量及从安慰剂转换至高剂量的患者(“Any secukinumab”高剂量组)。

主要发现

  • 司库奇尤单抗治疗患者至第104周PASI 75/90/100和IGA mod 2011 0/1应答持续维持。
  • 第2年治疗期间,PASI 75和IGA mod 2011 0/1应答在“Any secukinumab”低剂量组和高剂量组间相似。
  • PASI 90/100应答在剂量组间至第88周大多可比,但第104周时“Any secukinumab”高剂量组高于低剂量组。
  • CDLQI 0/1应答持续维持,“Any secukinumab”低剂量组为61.1%,高剂量组为65.0%。
  • 安全性数据与司库奇尤单抗已知安全性特征一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab has previously demonstrated sustained efficacy and favourable safety for up to 52 weeks in paediatric patients (children and adolescents aged 6 to <18 years) with severe chronic plaque psoriasis (NCT02471144). OBJECTIVE: To investigate the long-term (104 weeks) efficacy and safety of secukinumab. METHODS: After 52 weeks, patients continued to receive secukinumab low dose (LD [75/150 mg]) or high dose (HD [75/150/300 mg]). Patients on etanercept (0.8 mg/kg) until Week 52 entered follow-up. Data for patients receiving secukinumab LD from the beginning and those switching to secukinumab LD from placebo ('Any secukinumab' LD) and patients receiving secukinumab HD from the beginning and those switching to secukinumab HD from placebo ('Any secukinumab' HD) are presented. ASSESSMENTS: Psoriasis Area and Severity Index (PASI) score, PASI (75/90/100) responses, Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response, Children's Dermatology Life Quality Index (CDLQI) score and CDLQI 0/1 response up to Week 104, and, safety up to Week 104 for all patients and up to 4 years for some patients (~320 patient-years [PY] of treatment). RESULTS: Secukinumab-treated patients showed sustained PASI 75/90/100 and IGA mod 2011 0/1 responses up to Week 104. Throughout the second year of treatment, efficacy was similar for the 'Any secukinumab' LD and HD groups for PASI 75 and IGA mod 2011 0/1 responses. PASI 90/100 responses were mostly comparable between the dose groups up to Week 88, but higher in the 'Any secukinumab' HD than the 'Any secukinumab' LD group at Week 104. Patients achieved a sustained CDLQI 0/1 response that was similar between the 'Any secukinumab' LD (61.1%) and HD (65.0%) groups. Safety data were consistent with the established safety profile of secukinumab. CONCLUSION: Secukinumab demonstrated sustained long-term efficacy (up to 2 years) and a favourable safety profile (~320 PY of treatment) in paediatric patients with severe chronic plaque psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Krasowska D, Gambichler T, Cortés C, et al. Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomized controlled trial. J Eur Acad Dermatol Venereol. 2023. PMID: 36971771. doi:10.1111/jdv.19063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。